



ITW
Attorney Docket No. VPI/02-137 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/808,678
Confirmation No.: 6199
Filing Date: March 25, 2004
Examiner: Amelia A. Owens
Group Art Unit: 1625
Applicants: Jeremy Green et al.
For: COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES

May 16, 2007
Cambridge, Massachusetts

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

- (a) Pursuant to 37 C.F.R. §1.56, it is requested that the documents listed on the accompanying Form 1449/PTO be considered and made of record in the above-identified patent application.

- ☒ Copies of references Citation No(s). C10 – C15 are attached.
- ☐ Copy(ies) of references Citation No(s). _____ was/were filed in application U.S. Application No(s). _____ filed _____, from which this application claims priority under 35 U.S.C. § 120.
- ☐ A copy of the International Search Report received in the corresponding PCT Application No. _____ is attached herewith.

- (b) ☐ No fee is believed due because:

- ☐ The Information Disclosure Statement is being filed within three (3) months of the filing date of the application.
- ☐ The Information Disclosure Statement is being concurrently filed with the above-identified application.
- ☐ The Information Disclosure Statement is being concurrently filed with a Request for Continued Examination (RCE).
- ☐ The Information Disclosure Statement is being filed prior to the mailing of a first Office Action on the merits.

05/21/2007 CCHAU1 00000004 500725 10808678

01 FC:1806 180.00 DA

Rev. 3/2/05

Applicants: Jeremy Green et al.
Application No.: 10/808,678

- (c) ☒ The Information Disclosure Statement is being filed before the mailing date of any final action, notice of allowance or an action that otherwise closes prosecution; and
- ☐ Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; or
- ☒ The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.
- (d) ☐ The Information Disclosure Statement is being filed on or before the payment of the issue fee; and
- ☐ Each item of information contained in the Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement; or
- ☐ No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; and
- ☐ The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.

Applicants: Jeremy Green et al.
Application No.: 10/808,678

- ☒ The Director is hereby authorized to charge any additional fees that may be required for the Information Disclosure Statement, or credit any overpayment to Deposit Account No. 50-0725. A DUPLICATE COPY OF THIS LETTER IS ATTACHED.

Respectfully submitted,



Daniel A. Pearson, Reg. No. 58,053
Agent for Applicants
Karen E. Brown, Reg. No. 43,866
Attorney for Applicants
c/o Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, Massachusetts 02139
Tel: (617) 444-6790
Fax: (617) 444-6483

Modified Form 1449/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	10/808,678
	Filing Date	March 25, 2004
	First Named Inventor	Jeremy Green
	Group Art Unit	1625
	Examiner Name	Amelia A. Owens
	Attorney Docket Number	VPI/02-137 US

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date/Publication Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No		

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C10	Heideman et al., "Suppression of tumor growth, invasion and angiogenesis of human gastric cancer by adenovirus-mediated expression of NK ₄ ," <i>J. Gene Medicine</i> 6: 317-327 (2004).
	C11	Tomioka et al., "Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model," <i>Cancer Research</i> 61: 7518-7524 (2001).
	C12	Saga et al., "Expression of HGF/NK4 in ovarian cancer cells suppresses intraperitoneal dissemination and extends host survival," <i>Gene Therapy</i> 8: 1450-1455 (2001).
	C13	Martin et al., "Growth and angiogenesis of human breast cancer in a nude mouse tumour model is reduced by NK4, a HGF/SF antagonist," <i>Carcinogenesis</i> 24(8): 1317-1323 (2003).
	C14	Davies et al., "The HGF/SF antagonist NK4 reverses fibroblast- and HGF-induced prostate tumor growth and angiogenesis in vivo," <i>Int. J. Cancer</i> 106:348-354 (2003).
	C15	Christensen et al., "A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo," <i>Cancer Research</i> 63: 7345-7355 (2003).

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.